ReviewJournal of advanced research2026
Decoding Regnase-1's role in skin inflammation: potential therapeutic implication for dermatological disorders.
Review in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRegnase-1 is a multifunctional regulatory protein involved in immune modulation and inflammatory processes. As an endoribonuclease, it degrades mRNAs encoding pro-inflammatory cytokines, including IL-1β and IL-6. This makes it an essential factor in controlling immune cell function. Its role extends to various cell types, including keratinocytes and melanocytes, and it plays a pivotal part in maintaining skin homeostasis. Dysregulation of Regnase-1 has been implicated in various dermatological disorders, making it a significant target for understanding immune-related skin diseases. AIM OF REVIEW: This review provides a comprehensive analysis of Regnase-1's structure, function, and its diverse roles in skin biology. Specifically, it explores how Regnase-1 influences the pathogenesis of inflammatory skin diseases such as atopic dermatitis, psoriasis, and hidradenitis suppurativa, as well as its involvement in skin cancer development. By detailing Regnase-1's regulatory mechanisms, the review aims to highlight its potential as a therapeutic target and emphasize the need for further research on its specific functions across different skin diseases and immune responses. KEY SCIENTIFIC CONCEPTS OF REVIEW: Regnase-1 plays a crucial role in maintaining skin immune homeostasis by controlling the degradation of pro-inflammatory cytokine mRNAs, such as IL-1β, IL-6, and IL-17. It regulates inflammatory pathways in keratinocytes, melanocytes, and immune cells, preventing excessive immune activation. In atopic dermatitis, Regnase-1 deficiency leads to heightened Th2 responses and increased chemokine levels, while in psoriasis, it modulates the IL-23/Th17 axis and STAT3 pathways, impacting keratinocyte proliferation and chronic inflammation. Furthermore, in cancer, Regnase-1 acts as a tumor suppressor in melanoma by inhibiting the Akt/mTOR pathway, but its deficiency can promote squamous cell carcinoma through increased COX-2 expression. These context-specific functions make Regnase-1 a promising target for therapies that could modulate multiple inflammatory pathways, either simultaneously or specifically, offering novel approaches to treat chronic inflammatory skin disorders and cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.